[Long-term results of 2 therapeutic protocols in children with acute lymphoblastic leukemia of usual risk. Experience at the 20th of November National Medical Center]

Gac Med Mex. Mar-Apr 1998;134(2):145-51.
[Article in Spanish]

Abstract

The purpose of this study is to know the disease-free survival in children with acute lymphoblastic leukemia (ALL), submitted to two therapeutic programs. Habitual risk was defined as age older than 2 and younger than 10 years, without neurological, mediastinal or testicular infiltrations, leukocytes < 25 x 10(9)/l and morphologic cell type distinct of L-3. The first group (LAL81) included 30 patients, from 1981 to 1986, and they received: induction with vincristine (VCR) and prednisone (PDN); consolidation with mercaptopurine (MP), cytosine arabinoside (ARA) and doxorubicin (DOX); prophylaxis to the central nervous system (CNS) with radiotherapy and methotrexate (MTX)-ARA-hydrocortisone (HDR) intrathecal, and maintenance with MP and MTX. In the second group (LAL87), 28 patients were included from 1987 to 1993. They received: induction with VCR, PDN and lasparaginase (ASP); consolidation with MP, ARA, DOX, carmustine (BCNU) and cyclophosphamide (CFA); prophylaxis to the (CNS) with intrathecal MTX-ARA-HDR, and maintenance with MP and MTX. There was just one therapeutic failure. In the LAL81, protocol 11 relapses and 9 in LAL87 (p = 0.71) were observed. Of these, two in each group went to the CNS. The disease-free survival in LAL81 was 0.39 at 14 years; in LAL87, was 0.53 at 8 years (p = 0.62).

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Age Factors
  • Anti-Inflammatory Agents / therapeutic use
  • Antibiotics, Antineoplastic / therapeutic use
  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Asparaginase / therapeutic use
  • Carmustine / therapeutic use
  • Child
  • Child, Preschool
  • Cyclophosphamide / therapeutic use
  • Cytarabine / therapeutic use
  • Data Interpretation, Statistical
  • Disease-Free Survival
  • Doxorubicin / therapeutic use
  • Female
  • Humans
  • Hydrocortisone / therapeutic use
  • Male
  • Mercaptopurine / therapeutic use
  • Methotrexate / therapeutic use
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Prednisone / therapeutic use
  • Risk Factors
  • Time Factors
  • Vincristine / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Antibiotics, Antineoplastic
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents, Alkylating
  • Antineoplastic Agents, Hormonal
  • Antineoplastic Agents, Phytogenic
  • Cytarabine
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Mercaptopurine
  • Asparaginase
  • Carmustine
  • Prednisone
  • Hydrocortisone
  • Methotrexate